share_log

HOOKIPA Pharma | 424B5: Prospectus

HOOKIPA Pharma | 424B5: Prospectus

HOOKIPA Pharma | 424B5：募資說明書
美股SEC公告 ·  08/08 17:30

Moomoo AI 已提取核心訊息

HOOKIPA Pharma Inc. has announced an Open Market Sale Agreement with Jefferies LLC, allowing the sale of up to $50,000,000 of common stock. The agreement permits HOOKIPA Pharma to offer and sell its common stock through Jefferies, acting as a sales agent or principal. The previous sales agreement with SVB Securities LLC has been terminated, and no further sales will occur under that agreement. HOOKIPA Pharma's common stock is listed on the Nasdaq Capital Market under the symbol 'HOOK,' with a last reported sale price of $4.91 per share as of August 7, 2024. The sales are to be made in 'at the market offerings,' and Jefferies will receive a commission of 3.0% of the gross proceeds from any sales made under the agreement. Jefferies will also be considered an 'underwriter' within the meaning of the Securities Act, and will receive underwriting commissions or discounts. HOOKIPA Pharma has agreed to indemnify Jefferies against certain liabilities, including those under the Securities Act. The date of the prospectus supplement is August 8, 2024.
HOOKIPA Pharma Inc. has announced an Open Market Sale Agreement with Jefferies LLC, allowing the sale of up to $50,000,000 of common stock. The agreement permits HOOKIPA Pharma to offer and sell its common stock through Jefferies, acting as a sales agent or principal. The previous sales agreement with SVB Securities LLC has been terminated, and no further sales will occur under that agreement. HOOKIPA Pharma's common stock is listed on the Nasdaq Capital Market under the symbol 'HOOK,' with a last reported sale price of $4.91 per share as of August 7, 2024. The sales are to be made in 'at the market offerings,' and Jefferies will receive a commission of 3.0% of the gross proceeds from any sales made under the agreement. Jefferies will also be considered an 'underwriter' within the meaning of the Securities Act, and will receive underwriting commissions or discounts. HOOKIPA Pharma has agreed to indemnify Jefferies against certain liabilities, including those under the Securities Act. The date of the prospectus supplement is August 8, 2024.
HOOKIPA Pharma宣佈與Jefferies LLC達成公開市場銷售協議，允許最多銷售5000萬美元的普通股。該協議允許HOOKIPA Pharma通過充當銷售代理或主要負責人的Jefferies出售其普通股。先前與SVb Securities LLC之間的銷售協議已經終止，不會再有進一步的銷售。HOOKIPA Pharma的普通股在納斯達克資本市場上以"HOOk"符號上市，截至2024年8月7日最後報告的股價爲每股4.91美元。這些銷售將以"按市場發行"的方式進行，Jefferies將收取所銷售股票的總收益的3.0％作爲佣金。Jefferies也將被視爲《證券法》所定義的"承銷商"，並將獲得承銷佣金或折扣。HOOKIPA Pharma已同意對Jefferies承擔某些責任的賠償，包括《證券法》下的某些責任。配售補充協議的日期爲2024年8月8日。
HOOKIPA Pharma宣佈與Jefferies LLC達成公開市場銷售協議，允許最多銷售5000萬美元的普通股。該協議允許HOOKIPA Pharma通過充當銷售代理或主要負責人的Jefferies出售其普通股。先前與SVb Securities LLC之間的銷售協議已經終止，不會再有進一步的銷售。HOOKIPA Pharma的普通股在納斯達克資本市場上以"HOOk"符號上市，截至2024年8月7日最後報告的股價爲每股4.91美元。這些銷售將以"按市場發行"的方式進行，Jefferies將收取所銷售股票的總收益的3.0％作爲佣金。Jefferies也將被視爲《證券法》所定義的"承銷商"，並將獲得承銷佣金或折扣。HOOKIPA Pharma已同意對Jefferies承擔某些責任的賠償，包括《證券法》下的某些責任。配售補充協議的日期爲2024年8月8日。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間